Display options
Cite
Klieser E, Pichelstorfer M, Weyland D, et al. Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors. Mol Clin Oncol. 2016;4(5):763-773doi: 10.3892/mco.2016.819.
Klieser, E., Pichelstorfer, M., Weyland, D., Kemmerling, R., Swierczynski, S., Dinnewitzer, A., Jäger, T., Kiesslich, T., Neureiter, D., & Illig, R. (2016). Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors. Molecular and clinical oncology, 4(5), 763-773. https://doi.org/10.3892/mco.2016.819
Klieser, Eckhard, et al. "Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors." Molecular and clinical oncology vol. 4,5 (2016): 763-773. doi: https://doi.org/10.3892/mco.2016.819
Klieser E, Pichelstorfer M, Weyland D, Kemmerling R, Swierczynski S, Dinnewitzer A, Jäger T, Kiesslich T, Neureiter D, Illig R. Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors. Mol Clin Oncol. 2016 May;4(5):763-773. doi: 10.3892/mco.2016.819. Epub 2016 Mar 11. PMID: 27123276; PMCID: PMC4840821.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2016 May;4(5):763-773. doi: 10.3892/mco.2016.819. Epub 2016 Mar 11.

Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors.

Molecular and clinical oncology

Eckhard Klieser, Maximilian Pichelstorfer, Denis Weyland, Ralf Kemmerling, Stefan Swierczynski, Adam Dinnewitzer, Tarkan Jäger, Tobias Kiesslich, Daniel Neureiter, Romana Illig

Affiliations

  1. Institute of Pathology, Paracelsus Medical University/Salzburg General Hospital (SALK), A-5020 Salzburg, Austria.
  2. Institute of Pathology, Paracelsus Medical University/Salzburg General Hospital (SALK), A-5020 Salzburg, Austria; Bio- and Environmental Technology Program, University of Applied Sciences Upper Austria, A-4600 Wels, Austria.
  3. Department of Surgery, Paracelsus Medical University/Salzburg General Hospital (SALK), A-5020 Salzburg, Austria.
  4. Department of Internal Medicine I, Paracelsus Medical University/Salzburg General Hospital (SALK), A-5020 Salzburg, Austria; Laboratory for Tumor Biology and Experimental Therapies (TREAT), Institute of Physiology and Pathophysiology, Paracelsus Medical University, A-5020 Salzburg, Austria.

PMID: 27123276 PMCID: PMC4840821 DOI: 10.3892/mco.2016.819

Abstract

The aim of this study was to provide a standardized risk stratification model for gastrointestinal stromal tumors (GISTs) based on tumor localization, tumor size, involved lymph nodes and metastases, as well as mitotic activity and other morphological and molecular markers, in order to improve the risk evaluation scheme for recurrence, metastatic spread and survival for patients with GIST. A total of 201 cases of patients with GIST were investigated according to standardized morphological markers, including nuclear pleomorphism, tumor cell necrosis, mucosal infiltration, ulceration, skeinoid fibers and growth pattern. In addition, all cases were immunohistochemically analyzed using a tissue microarray platform for various markers of differentiation (CD34, CD44, CD117, desmin, discovered on GIST 1, platelet-derived growth factor receptor α, S-100 and smooth muscle actin) and proliferation (B-cell lymphoma 2, P16, P53, phosphohistone H3 and Ki-67). These findings were correlated by uni- and multivariable analyses with clinicopathological characteristics, including recurrence, metastasis and survival. The general clinicopathological parameters of this GIST specimen cohort were comparable to previous studies. While several parameters exhibited clear associations to each other and to the defined clinical endpoints, the multivariate analysis reduced the number of relevant prognostic variables to localization, margin status, growth pattern and hematoxylin and eosin-based mitosis/Ki-67-based proliferation of GISTs. With the exception of CD34, none of the applied markers of differentiation and proliferation were found to be independent prognostic markers in GIST and the classical risk factors of GIST remain important prognostic factors. Additionally, growth pattern may predict the risk of recurrence and metastasis in GIST patients. Additional independent molecular prognostic markers remain to be identified and validated.

Keywords: gastrointestinal stromal tumors; prognostic markers

References

  1. Am J Clin Oncol. 2003 Jun;26(3):221-8 - PubMed
  2. Int J Oncol. 2010 Jan;36(1):49-58 - PubMed
  3. World J Gastroenterol. 2007 Jan 21;13(3):426-31 - PubMed
  4. Int J Oncol. 2012 Aug;41(2):511-22 - PubMed
  5. Lancet Oncol. 2012 Mar;13(3):265-74 - PubMed
  6. PLoS One. 2013 May 17;8(5):e62951 - PubMed
  7. Asian Pac J Cancer Prev. 2013;14(8):4751-8 - PubMed
  8. Hum Pathol. 2002 May;33(5):459-65 - PubMed
  9. Am J Surg Pathol. 2011 Nov;35(11):1646-56 - PubMed
  10. Dtsch Med Wochenschr. 2013 Oct;138(40):2013-6 - PubMed
  11. Int J Clin Exp Pathol. 2012;5(1):12-22 - PubMed
  12. J Agric Food Chem. 2013 Sep 4;61(35):8340-8 - PubMed
  13. Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 - PubMed
  14. Pathologe. 2010 Sep;31(5):348-52 - PubMed
  15. Dev Dyn. 2013 Jan;242(1):53-66 - PubMed
  16. J Surg Oncol. 2011 Dec;104(8):865-73 - PubMed
  17. Cytopathology. 2007 Oct;18(5):283-9 - PubMed
  18. Semin Diagn Pathol. 2006 May;23(2):70-83 - PubMed
  19. Int J Surg Pathol. 2000 Apr;8(2):133-144 - PubMed
  20. Am J Surg Pathol. 1997 Apr;21(4):407-16 - PubMed
  21. RNA. 2009 Aug;15(8):1588-96 - PubMed
  22. Cancer. 2005 Feb 15;103(4):821-9 - PubMed
  23. Am J Surg Pathol. 1999 Jan;23(1):82-7 - PubMed
  24. Hum Pathol. 1998 Aug;29(8):791-800 - PubMed
  25. Virchows Arch. 2012 Feb;460(2):163-9 - PubMed
  26. Hum Pathol. 2002 May;33(5):478-83 - PubMed
  27. Oncol Lett. 2014 Mar;7(3):745-749 - PubMed
  28. Int J Surg. 2014;12(4):269-80 - PubMed
  29. Ann Oncol. 2012 Oct;23 Suppl 7:vii49-55 - PubMed
  30. Oncol Rep. 2010 May;23(5):1261-7 - PubMed
  31. World J Gastroenterol. 2013 Apr 28;19(16):2473-80 - PubMed
  32. Tohoku J Exp Med. 2014;233(1):65-72 - PubMed

Publication Types